mkrasvax
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 27, 2025 (NCT06782932)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- GTPase KRasImmunity, active
KRAS immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06782932 | Phase 1/Phase 2 (Phase 2) | May 27, 2025 | Agenus Inc., Johns Hopkins University, Lustgarten Foundation, Oncovir, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Agenus Inc. | For profit | 1 | 0 | 1 | 2025 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Lustgarten Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1